Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00458822 · ClinicalTrials.gov registry record · Phase 2

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00458822 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00458822, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease.

Conditions Studied

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

  • DRUG dexamethasone
  • DRUG bortezomib

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2007-02
Est. Completion 2015-03
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00458822

The ClinicalTrials.gov registry entry for NCT00458822 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which dexamethasone is the first listed.

NCT00458822 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00458822 about?

NCT00458822 is a clinical study titled "Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis". The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to ...

What is the current status of trial NCT00458822?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-02. Estimated completion is 2015-03.

What conditions does trial NCT00458822 study?

This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.

What interventions are being tested in trial NCT00458822?

The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG).

Who is sponsoring clinical trial NCT00458822?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00458822 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma and Plasma Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma and Plasma Cell Neoplasm

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.